Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.52 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524136 | 1.00 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL10030564 | 0.91 | SLC6A1 (0.57) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL2223343 | 0.90 | SLC6A1 (0.49) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL16364960 | 0.89 | GNAI3 (0.49) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL17377633 | 0.86 | SLC6A1 (0.55) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL29542338 | 0.85 | SLC6A1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL16528361 | 0.85 | SLC6A1 (0.55) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL13285080 | 0.85 | CHRNB2 (0.57) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Tert-Butyl Formate SCHEMBL28039935 | 0.84 | SLC6A1 (0.38) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Tert-Butyl Formate SCHEMBL28039929 | 0.84 | SLC6A1 (0.38) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249155-B2 | Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia | XENTION LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249155-B2 | Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia | XENTION LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20140206703-A1 | THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| US-20140206703-A1 | THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-1919471-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | MERCK SHARP & DOHME (NL) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012131379-A1 | THIENO [2, 3 -D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | XENTION LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| US-7763732-B2 | 7-Chloro-3-({5-[N-(morpholin-1-ylcarboxamido)methyl]aminomethyl}-([1,2,4]-thiadiazol-3-yl))-1-(tetrahydropyran-4-yl)methyl-1H-indole, hydrochloride salt; treatment of pain | N.V. ORGANON (NL) | 2010-07-27 | — | — | US | disclosed |
| US-20090029984-A1 | SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABINOID RECEPTOR AGONIST AND OPIOID RECEPTOR AGONIST) | N.V. ORGANON (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20070082931-A1 | Indole derivatives | AKZO NOBLE N.V. (NL) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082931-A1 | Indole derivatives | IDO1, TPH1, IDO2 | SLC6A1 439/4885SLC6A11 484/4885TSHR 2086/4885 |
| US-20140206703-A1 | THIENO [2, 3-D] PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA | KCNJ2, KCNH2, KCNH1 | SLC6A1 992/4885SLC6A11 944/4885TSHR 1769/4885 |
| US-20090029984-A1 | SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABINOID RECEPTOR AGONIST AND OPIOID RECEPTOR AGONIST) | CNR1, OPRL1, CNR2 | SLC6A1 473/4885SLC6A11 513/4885TSHR 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.